Mondoh. Alvin A; Crotty. Michael M; le Roux. Carel W CW
The review compares two popular weight‑loss drugs—semaglutide (Ozempic) and tirzepatide (Mounjaro). It shows that both work well for obesity, but tirzepatide tends to cause bigger drops in weight while semaglutide is especially strong at protecting the heart. The paper pulls together results from big clinical trials to help people decide which drug might fit their goals.
ElBadawi. Hussein H; Albalkhi. Nader N; Al Kadhim. Ibrahim I; Elsadig. Ahmed A; Baltzis. Dimitrios D...
In a real‑world study of 192 Saudi adults with type 2 diabetes who started daily oral semaglutide, blood sugar (HbA1c) dropped about 1 % and body weight fell roughly 4.4 kg over 8‑10 months. Most people felt more satisfied with their treatment, and about half stayed on the drug, mainly at the 14 mg dose.
Wood. Emily E; Akande. Rukayat R; Iqbal. Iqra I; Albert. Stewart G SG
A big analysis of 14 clinical trials shows that semaglutide, a drug already on the market, can significantly improve liver inflammation and fibrosis in people with advanced fatty liver disease. The benefits are strongest when treatment starts early, before the scarring gets too severe.
Semaglutide, a drug already used for type 2 diabetes, also helps protect the kidneys in people with diabetic kidney disease. It does this not just by lowering blood sugar, but also by reducing inflammation, lowering blood pressure inside the kidneys, and improving how the kidneys filter blood. The review pulls together lab studies, clinical trials, and real‑world data showing these kidney benefits, making semaglutide a strong candidate for anyone looking to keep their kidneys healthy while managing diabetes.
Lehenbauer. Katy S KS; Nelson. Adam J AJ; Nodari. Savina S; Sverdlov. Aaron L AL; Harrington. Joseph...
A big study (SOUL) showed that taking the pill form of semaglutide cuts the chance of heart attacks, strokes, and cardiovascular death by about 14% in people with type 2 diabetes who already have heart or kidney disease. The benefit was seen no matter if they were also on other heart‑protective drugs.
Erlandson. Kristine M KM; Kitch. Douglas W DW; Kantor. Amy A; Belaunzaran-Zamudio. Pablo F PF; Brown...
In a study of people with HIV, taking a low dose of semaglutide (1 mg weekly) for six months led to an average loss of about 8 kg. When the drug was stopped, participants regained roughly 3 kg over the next six months, and some of the blood‑sugar improvements slipped away, though cholesterol and blood pressure stayed about the same.
Albarmawi. Husam H; Dabbous. Firas F; Aly. Abdalla A; Yousif. Alia A; Huse. Samuel S; Jara. Maximili...
In people who are overweight or obese and have fatty liver disease, taking semaglutide for six months cut liver enzymes (ALT and AST) by about a third, helped them lose roughly 5% of their body weight, and lowered blood sugar (HbA1c) by a similar amount. These changes were much bigger than what was seen in a large group of similar people who didn’t use any anti‑obesity drugs.
A large real‑world study found that people with type‑2 diabetes who start a GLP‑1 receptor agonist (like semaglutide) are about 15‑30% less likely to develop epilepsy compared with those who start a DPP‑4 inhibitor. The protective effect was seen early and persisted for several years, with semaglutide showing the strongest benefit.
Sass. Marie R MR; Klausen. Mette Kruse MK; Schwarz. Christine R CR; Rasmussen. Line L; Giver. Malte...
In a 26‑week trial, people with schizophrenia who were taking weight‑gain‑causing antipsychotic drugs lost about 9 kg, dropped around 7 cm from their waist, and lowered their blood‑sugar marker (HbA1c) by a quarter of a percent when they added a weekly 1 mg dose of semaglutide, compared with a placebo. The drug was well‑tolerated, with only mild stomach upset, and didn’t worsen psychiatric symptoms.
In a study of teens with obesity, a once‑weekly injection of semaglutide (2.4 mg) cut body‑mass index by about 17% after 68 weeks and also made the body more insulin‑sensitive, lowered blood sugar, reduced liver enzymes, and improved cholesterol and triglycerides. Bigger weight loss (≥20%) gave even stronger metabolic benefits.
The review says that if you’re a woman of child‑bearing age using semaglutide (or similar GLP‑1 drugs) and you want to get pregnant, you should stop the drug well before trying – about 35 days for semaglutide and 25‑35 days for tirzepatide, based on how long they stay in the body. Early accidental exposure hasn’t shown clear birth defects, but the data are limited, so safer options like metformin, diet changes, or bariatric surgery are still preferred for pre‑pregnancy weight loss.
Ahmad. Omar O; Ibrahim. Ramzi R; Pham. Hoang Nhat HN; Abdelnabi. Mahmoud M; Elbenawi. Hossam H; Sali...
Starting a GLP‑1 receptor agonist like semaglutide (or tirzepatide) within two weeks after a heart attack in people with type‑2 diabetes didn’t cut the chance of another heart‑attack, but it cut the risk of dying, heart‑failure trips to the hospital, kidney injury, cardiac arrest, and overall hospital stays by roughly 30‑50% over about a year.
Jaradat. Jaber H JH; Al-Ahmad. Rawan I RI; Al Jaghbeer. Maha M; Abdelaziz. Ahlam A AA; Abu Afifeh. N...
GLP‑1 drugs like semaglutide help people lose weight and lower blood sugar, but some studies suggest they might raise the chance of certain cancers, especially thyroid and pancreatic cancers. The evidence isn’t conclusive, but there’s a signal that one drug (liraglutide) showed a higher cancer risk, and semaglutide’s data are mixed. So, while these drugs are effective, you should be cautious if you have a history or family risk of those cancers.
A recent observational study in diabetic patients who had heart bypass surgery found that tirzepatide, compared to semaglutide, was linked to lower risks of stroke, heart problems, blood clots, death, and fewer hospital visits. The researchers think this may be due to tirzepatide’s extra GIP‑receptor action, since semaglutide didn’t show a stroke benefit in other trials. The findings are preliminary but suggest tirzepatide could offer extra brain‑vascular protection in very high‑risk people.
Mandal. Laura L; Andersen. Louise Udby LU; Luef. Birgitte Møller BM; Tanvig. Mette Honnens MH;...
The review looked at 5 studies with over a thousand pregnancies where the mother had taken semaglutide, a drug used for weight loss and diabetes. The results were mixed – some reports of miscarriage and pre‑eclampsia, a few birth defects but not more than with insulin, and some babies being larger than normal if the drug was stopped early. Overall, there’s no solid proof that semaglutide causes major birth defects, but the data are limited and not consistent.
Chaible. Lucas L; Preillon. Julie J; Philippart. Charlotte C; Canevat. Alizée A; Saerens. Laura...
A new drug that blocks the ENT1 transporter (called EOS-518) helped obese mice lose weight, eat less, and improve blood sugar and cholesterol. It worked even better when paired with the popular weight‑loss peptide semaglutide, and adding it after semaglutide stopped working gave extra loss. This points to ENT1 as a promising new target for obesity treatment, but the drug isn’t available yet.
In mice, long‑term semaglutide causes weight loss in three phases: a quick drop from eating less and burning more fat, a slower loss where meals get smaller but you eat more often, and a steady maintenance period. When the drug stops, mice quickly regain weight because they start eating larger, more frequent meals and their bodies shift back to burning carbs. The study shows that the drug’s effects on appetite and metabolism change over time and reverse fast after stopping.
Ibrahim. Ramzi R; Han. William W; Wang. Winston W; Kau. Ethan E; Said. Nada N; Forst. Beani B; Pham....
In a large real‑world study, people with obesity and a type of heart failure called HFpEF who took GLP‑1 drugs like semaglutide did better than those who had weight‑loss surgery. They had fewer heart‑failure flare‑ups, lived longer, and spent less time in the hospital, while losing about the same amount of weight. This suggests GLP‑1 drugs can be a powerful, non‑surgical option for managing weight and heart health in this high‑risk group.
Current evidence from a large meta‑analysis of 48 trials (about 94,000 people) shows that semaglutide and similar GLP‑1 drugs probably don’t raise the risk of most obesity‑related cancers, like thyroid, pancreatic, breast, or kidney cancer, and may have little effect on others. However, the studies were short‑term and not built to detect cancer, so long‑term safety still isn’t fully known.
Alansari. Amal Omar AO; Alharbi. Ahlam Saleem AS; Alshehri. Khaled Mohammad KM; Alhabib. Ali Tareq A...
A big review looked at whether weight‑loss drugs that act like GLP‑1 (including semaglutide) increase thoughts of suicide or actual suicide. Overall, the drugs didn’t raise the risk compared to other diabetes or obesity medicines, but one drug, liraglutide, showed a higher suicide rate than semaglutide. The evidence isn’t strong enough to change anything dramatically, but it suggests semaglutide is not linked to higher suicidality, while liraglutide might need extra caution.